Researchers at University of Galway have been awarded European Research Council funding supports to progress two research projects.
The awards are among 182 projects across Europe which have been awarded ERC Proof of Concept grants to explore the commercial or societal potential of their research. Two projects from University of Galway will receive the prestigious funding support, one on an AI-assisted clinical support tool and another to improve next-generation regenerative medicines.
One project, iChatRD, will develop a user-centred clinical decision support system for the diagnosis of rare and inherited metabolic diseases. The project has been awarded a grant of €150,000 and will run for 18 months. The AI-assisted, fully transparent clinical decision support tool suggests expert-level rare disease diagnoses from unstructured patient descriptions within seconds. The project is led by Professor Ines Thiele and Research Fellow, Dr Cyrille Thinnes from the School of Medicine, School of Biological and Chemical Sciences and the Digital Metabolic Twin Centre at the University of Galway.
“This funding gives us the opportunity to turn ChatRD, currently a research tool, into something clinicians can, and want to, use in their daily practice,” said Dr Thinnes. “Our goal is to put a reliable decision support system in the hands of the doctor who sees a patient on day one, not year five.
“Crucially, every suggestion ChatRD produces is fully explainable, so the clinician can see exactly why a disease was flagged, which we believe is essential for fostering trust in AI-assisted medicine.”
The overall goal of the project is to translate the research prototype into a practical, clinically relevant tool, which is also aligned with regulatory requirements and market needs. The team will develop ChatRD2.0 through best practices in engaged research, working side by side with metabolic disease specialists, paediatricians, and frontline clinicians to ensure the tool is shaped by the people who will actually use it.
Professor Thiele believes that the grant helps take iChatRD into the “real world, by working directly with clinicians to help shorten the diagnostic odyssey that may burden rare disease patients for years”.
The second project, GelEV has been awarded a grant of €150,000 and will run for 18 months. It will focus on the development of a new technology that could significantly improve the delivery of next-generation regenerative medicines for tissue injury. The project aims to validate a novel hydrogel designed to deliver extracellular vesicles (EVs ), tiny particles secreted by cells, allowing them to work more effectively.
This project is led by principal investigator Dr Meadhbh Brennan and technical lead Dr Hannah Aris from the School of Engineering at University of Galway.
“By creating a delivery platform compatible with a wide range of EV therapies, the GelEV ERC proof-of-concept project has the potential to accelerate the development of new treatments for tissue injury indications, while supporting the growing extracellular vesicles therapeutics industry,” said Dr Brennan.
The European Research Council Proof of Concept scheme is funded under Horizon Europe, the EU’s framework programme for research and innovation.
